Lupin Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
889.05 +8.25 (0.94%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
876.1
Today’s High
894.4
52 Week Low
602.8
52 Week High
889.9
2043.00 +4.80 (0.24%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
2008.5
Today’s High
2065
52 Week Low
1183.55
52 Week High
2312
Key Metrics
- Market Cap (In Cr) 92982.19
- Beta 0.74
- Div. Yield (%) 0.39
- P/B 6.5
- TTM P/E 38.02
- Peg Ratio 2.2
- Sector P/E 31.15
- D/E 0.22
- Open Price 881
- Prev Close 880.8
Lupin Analysis
Price Analysis
-
1 Week-2.24%
-
3 Months-2.72%
-
6 Month21.04%
-
YTD54.06%
-
1 Year70.06%
Risk Meter
- 27% Low risk
- 27% Moderate risk
- 27% Balanced Risk
- 27% High risk
- 27% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 6
- 6
- 5
- 5
- Buy
- 9
- 9
- 6
- 6
- Hold
- 9
- 9
- 10
- 10
- Sell
- 6
- 6
- 8
- 7
- Strong Sell
- 2
- 2
- 2
- 2
- Total
- 32
- 32
- 31
- 30
Lupin News
This multi-billion dollar opportunity could be a game changer for Wockhardt
8 min read . 06:00 AM ISTBuy or sell: Vaishali Parekh recommends three stocks for today — October 31
2 min read . 31 Oct 2024Lupin Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 20010.82
- Selling/ General/ Admin Expenses Total
- 3494.57
- Depreciation/ Amortization
- 1196.81
- Other Operating Expenses Total
- 6072.77
- Total Operating Expense
- 17407.62
- Operating Income
- 2603.2
- Net Income Before Taxes
- 2422.27
- Net Income
- 1914.48
- Diluted Normalized EPS
- 41.87
- Period
- 2024
- Total Assets
- 23997.18
- Total Liabilities
- 9706.89
- Total Equity
- 14290.29
- Tangible Book Valueper Share Common Eq
- 222.39
- Period
- 2024
- Cashfrom Operating Activities
- 3648.36
- Cashfrom Investing Activities
- -1712.2
- Cashfrom Financing Activities
- -2184.21
- Net Changein Cash
- -248.05
- Period
- 2023
- Total Revenue
- 16641.66
- Selling/ General/ Admin Expenses Total
- 7019.52
- Depreciation/ Amortization
- 841.31
- Other Operating Expenses Total
- 156.81
- Total Operating Expense
- 15760.01
- Operating Income
- 881.65
- Net Income Before Taxes
- 716.49
- Net Income
- 430.08
- Diluted Normalized EPS
- 9.66
- Period
- 2023
- Total Assets
- 22955.93
- Total Liabilities
- 10491.43
- Total Equity
- 12464.5
- Tangible Book Valueper Share Common Eq
- 184.87
- Period
- 2023
- Cashfrom Operating Activities
- 1897.24
- Cashfrom Investing Activities
- -1286.77
- Cashfrom Financing Activities
- -337.25
- Net Changein Cash
- 273.22
- Period
- 2022
- Total Revenue
- 16405.48
- Selling/ General/ Admin Expenses Total
- 6625.43
- Depreciation/ Amortization
- 818.5
- Other Operating Expenses Total
- 150.84
- Total Operating Expense
- 17799.47
- Operating Income
- -1393.99
- Net Income Before Taxes
- -1372.21
- Net Income
- -1528.04
- Diluted Normalized EPS
- 5.26
- Period
- 2022
- Total Assets
- 21821.22
- Total Liabilities
- 9667.95
- Total Equity
- 12153.27
- Tangible Book Valueper Share Common Eq
- 198.53
- Period
- 2022
- Cashfrom Operating Activities
- 367.31
- Cashfrom Investing Activities
- 1292.23
- Cashfrom Financing Activities
- -1572.32
- Net Changein Cash
- 87.22
- Period
- 2021
- Total Revenue
- 15162.96
- Selling/ General/ Admin Expenses Total
- 6556.71
- Depreciation/ Amortization
- 887.41
- Other Operating Expenses Total
- 122.82
- Total Operating Expense
- 13472.14
- Operating Income
- 1690.82
- Net Income Before Taxes
- 1676.45
- Net Income
- 1216.53
- Diluted Normalized EPS
- 26.71
- Period
- 2021
- Total Assets
- 23610.44
- Total Liabilities
- 9807.3
- Total Equity
- 13803.14
- Tangible Book Valueper Share Common Eq
- 222.42
- Period
- 2021
- Cashfrom Operating Activities
- 1821.76
- Cashfrom Investing Activities
- -1239.58
- Cashfrom Financing Activities
- -1885.27
- Net Changein Cash
- -1303.09
- Period
- 2020
- Total Revenue
- 15374.76
- Selling/ General/ Admin Expenses Total
- 6880.23
- Depreciation/ Amortization
- 970.22
- Other Operating Expenses Total
- 162.79
- Total Operating Expense
- 14715.68
- Operating Income
- 659.08
- Net Income Before Taxes
- 757.23
- Net Income
- -269.39
- Diluted Normalized EPS
- 1.98
- Period
- 2020
- Total Assets
- 24983.85
- Total Liabilities
- 12447.15
- Total Equity
- 12536.7
- Tangible Book Valueper Share Common Eq
- 193.88
- Period
- 2020
- Cashfrom Operating Activities
- 1468.84
- Cashfrom Investing Activities
- 1106.99
- Cashfrom Financing Activities
- -890.58
- Net Changein Cash
- 1685.25
- Period
- 2019
- Total Revenue
- 14664.56
- Selling/ General/ Admin Expenses Total
- 6587.88
- Depreciation/ Amortization
- 846.05
- Other Operating Expenses Total
- 122.04
- Total Operating Expense
- 13283.58
- Operating Income
- 1380.98
- Net Income Before Taxes
- 1408.96
- Net Income
- 606.55
- Diluted Normalized EPS
- 16.17
- Period
- 2019
- Total Assets
- 27949.37
- Total Liabilities
- 14207.14
- Total Equity
- 13742.23
- Tangible Book Valueper Share Common Eq
- 153.5
- Period
- 2019
- Cashfrom Operating Activities
- 1665.97
- Cashfrom Investing Activities
- -3282.47
- Cashfrom Financing Activities
- 744.13
- Net Changein Cash
- -872.37
- Period
- 2024-09-30
- Total Revenue
- 5672.73
- Selling/ General/ Admin Expenses Total
- 1007.52
- Depreciation/ Amortization
- 256.92
- Other Operating Expenses Total
- 1666.99
- Total Operating Expense
- 4621.37
- Operating Income
- 1051.36
- Net Income Before Taxes
- 1054.86
- Net Income
- 852.58
- Diluted Normalized EPS
- 18.64
- Period
- 2024-09-30
- Total Assets
- 25481.96
- Total Liabilities
- 9840.13
- Total Equity
- 15641.83
- Tangible Book Valueper Share Common Eq
- 249.82
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1174.09
- Cashfrom Investing Activities
- -1024.22
- Cashfrom Financing Activities
- 0.82
- Net Changein Cash
- 150.69
- Period
- 2024-06-30
- Total Revenue
- 5600.33
- Selling/ General/ Admin Expenses Total
- 971.04
- Depreciation/ Amortization
- 247.71
- Other Operating Expenses Total
- 1598.37
- Total Operating Expense
- 4561.68
- Operating Income
- 1038.65
- Net Income Before Taxes
- 993.03
- Net Income
- 801.31
- Diluted Normalized EPS
- 17.52
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 4960.79
- Selling/ General/ Admin Expenses Total
- 900.22
- Depreciation/ Amortization
- 457.1
- Other Operating Expenses Total
- 1489.97
- Total Operating Expense
- 4421.13
- Operating Income
- 539.66
- Net Income Before Taxes
- 497.71
- Net Income
- 359.43
- Diluted Normalized EPS
- 7.86
- Period
- 2024-03-31
- Total Assets
- 23997.18
- Total Liabilities
- 9706.89
- Total Equity
- 14290.29
- Tangible Book Valueper Share Common Eq
- 222.39
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 3648.36
- Cashfrom Investing Activities
- -1712.2
- Cashfrom Financing Activities
- -2184.21
- Net Changein Cash
- -248.05
- Period
- 2023-12-31
- Total Revenue
- 5197.41
- Selling/ General/ Admin Expenses Total
- 889.24
- Depreciation/ Amortization
- 257.2
- Other Operating Expenses Total
- 1560.13
- Total Operating Expense
- 4432.65
- Operating Income
- 764.76
- Net Income Before Taxes
- 736.1
- Net Income
- 613.12
- Diluted Normalized EPS
- 13.41
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 5038.56
- Selling/ General/ Admin Expenses Total
- 860.71
- Depreciation/ Amortization
- 247.85
- Other Operating Expenses Total
- 1551.94
- Total Operating Expense
- 4363.27
- Operating Income
- 675.29
- Net Income Before Taxes
- 629.67
- Net Income
- 489.67
- Diluted Normalized EPS
- 10.72
- Period
- 2023-09-30
- Total Assets
- 23443.65
- Total Liabilities
- 10204.91
- Total Equity
- 13238.74
- Tangible Book Valueper Share Common Eq
- 193.45
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 1708.33
- Cashfrom Investing Activities
- -315.71
- Cashfrom Financing Activities
- -1148.45
- Net Changein Cash
- 244.17
- Period
- 2023-06-30
- Total Revenue
- 4814.06
- Selling/ General/ Admin Expenses Total
- 844.4
- Depreciation/ Amortization
- 234.66
- Other Operating Expenses Total
- 1472.41
- Total Operating Expense
- 4192.25
- Operating Income
- 621.81
- Net Income Before Taxes
- 558.79
- Net Income
- 452.26
- Diluted Normalized EPS
- 9.9
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 4430.08
- Selling/ General/ Admin Expenses Total
- 772.99
- Depreciation/ Amortization
- 263.99
- Other Operating Expenses Total
- 1303
- Total Operating Expense
- 4090.02
- Operating Income
- 340.06
- Net Income Before Taxes
- 258.5
- Net Income
- 235.96
- Diluted Normalized EPS
- 5.16
- Period
- 2023-03-31
- Total Assets
- 22955.93
- Total Liabilities
- 10491.43
- Total Equity
- 12464.5
- Tangible Book Valueper Share Common Eq
- 184.87
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 1897.24
- Cashfrom Investing Activities
- -1286.77
- Cashfrom Financing Activities
- -337.25
- Net Changein Cash
- 273.22
- Period
- 2022-12-31
- Total Revenue
- 4322.22
- Selling/ General/ Admin Expenses Total
- 764
- Depreciation/ Amortization
- 220.4
- Other Operating Expenses Total
- 1335.06
- Total Operating Expense
- 4026.58
- Operating Income
- 295.64
- Net Income Before Taxes
- 246.14
- Net Income
- 153.47
- Diluted Normalized EPS
- 3.36
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Lupin Technical
Moving Average
SMA
- 5 Day2051.82
- 10 Day2100.77
- 20 Day2129.95
- 50 Day2181.52
- 100 Day2046.03
- 300 Day1824.84
Lupin Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Dr Reddys Laboratories
- 1194.55
- -19.4
- -1.6
- 1420.2
- 1074.35
- 19892.66
- Zydus Lifesciences
- 942
- -4.9
- -0.52
- 1323.9
- 628.05
- 94765.2
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40512.13
- Alkem Laboratories
- 5601
- 75.75
- 1.37
- 6440
- 4382.25
- 66959.96
- Abbott India
- 27165
- -28.8
- -0.11
- 30499.9
- 21983.4
- 57723.72
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Dr Reddys Laboratories
- 18.36
- 3.58
- 16.73
- 14.63
- Zydus Lifesciences
- 24.99
- 4.81
- 15.65
- 14.33
- Lupin
- 44.93
- 6.5
- 2.51
- 2.04
- Alkem Laboratories
- 36.76
- 6.41
- 18.26
- 13.94
- Abbott India
- 48.16
- 15.64
- 30.46
- 17.26
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 07-Nov-24
- Quarterly Results
- 06-Aug-24
- Quarterly Results
- 06-May-24
- Audited Results & Final Dividend
- 07-Feb-24
- Quarterly Results
- 08-Nov-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 09-May-23
- Audited Results & Final Dividend
- 09-Feb-23
- Quarterly Results
- 09-Nov-22
- Quarterly Results
- 03-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 02-Aug-24
- 09-Jul-24
- AGM
- 03-Aug-23
- 10-Jul-23
- AGM
- 03-Aug-22
- 05-Jul-22
- AGM
- 11-Aug-21
- 15-Jul-21
- AGM
- 18-Mar-21
- 12-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 06-May-24
- 16-Jul-24
- 16-Jul-24
- 8
- 10-May-23
- 14-Jul-23
- 14-Jul-23
- 4
- 18-May-22
- 15-Jul-22
- 14-Jul-22
- 4
- 14-May-21
- 28-Jul-21
- 27-Jul-21
- 6.5